Dec 23 (Reuters) - Benitec Biopharma Ltd BLT.AX
* Benitec Biopharma Ltd - Agreement to develop a clinical stage asset to treat head and Neck Squamous Cell Carcinoma
* Benitec Biopharma Ltd - Has executed an exclusive, world-wide sublicensing agreement that will enable Benitec, in collaboration with NantWorks
* Benitec Biopharma - Will work with NantWorks to finalize terms of its scientific collaboration with a targeted date for execution of 27 January, 2017 Source text for Eikon: ID:nPn5B3P6da Further company coverage: BLT.AX